Most Americans Carrying Genetic Variants for Alpha-1 Antitrypsin Deficiency Lack Diagnoses

Most individuals carrying genetic variants linked to alpha-1 antitrypsin deficiency in the United States remain without a documented clinical diagnosis, according to a cross-sectional, multi-population investigation published in BMC Gastroenterology. Drawing on genetic profiles and medical records from large-scale epidemiological cohorts and electronic medical record-linked biobanks, researchers determined that overall recorded diagnosis rates among genotype carriers were below two percent.

Alpha-1 antitrypsin deficiency represents an inherited disorder that clinicians frequently fail to identify in standard care. To evaluate the scope of this underdiagnosis, the investigative team set out to measure the prevalence of deficiency-associated genotypes, assess formal clinical identification rates, and characterize patient profiles using data from major American epidemiological studies alongside the All of Us and BioVU biobank repositories.

The study population was assembled by identifying participants who carried specific deficiency-associated genotypes, designated as protease inhibitor alleles MS, MZ, SS, SZ, and ZZ. While investigators calculated the prevalence of these genetic profiles across all examined cohorts, they restricted their analysis of clinical diagnosis rates and individual patient traits specifically to individuals registered in the All of Us and BioVU electronic medical record-linked biobanks.

To evaluate how frequently carriage of these alleles translated into formal medical recognition, investigators analyzed patient records for the presence of at least one International Classification of Diseases diagnostic code corresponding to alpha-1 antitrypsin deficiency. These rates were evaluated across the broader cohort of identified carriers as well as within individual genotype categories.

Demographic evaluations across the contributing data sources revealed mean participant ages ranging between 42.6 and 64.2 years. A numerically higher proportion of participants identified as female, spanning 55.2 to 63.2 percent across cohorts when excluding the all-female Women’s Health Initiative group. Furthermore, White individuals constituted between 53.2 and 92.3 percent of the analyzed populations across data sources.

Upon standardizing prevalence estimates to the broader United States population, researchers calculated that the high-risk protease inhibitor ZZ genotype occurred at a rate ranging from 24 to 76 cases per 100,000 people. Despite this substantial underlying frequency, documented diagnosis rates across the entire spectrum of analyzed deficiency genotypes remained below 2.0 percent in medical records.

Clinical documentation differed significantly when researchers isolated individuals possessing the homozygous protease inhibitor ZZ genotype. Within this specific subset, formal diagnosis rates rose to 51.5 percent in the All of Us repository and reached 68.7 percent in the BioVU cohort, demonstrating that medical recognition was concentrated predominantly among patients carrying the severe homozygous genotype.

Patients who had a documented diagnostic code for the condition exhibited higher rates of comorbidities, including liver disease, lung disease, diabetes, obesity, and thrombocytopenia, along with elevated biomarkers indicative of hepatic impairment. The authors concluded that the low rates of documented diagnoses among individuals with risk-associated genotypes highlight the necessity of enhanced screening initiatives to identify undiagnosed individuals across the United States.

Subject of Research: Diagnosis rates and epidemiology of alpha-1 antitrypsin deficiency genotypes in the United States

Article Title: Epidemiology and diagnosis rates of alpha-1 antitrypsin deficiency-associated genotypes in the USA: a cross-sectional, multi-population study

Article References: Zhang, X., Evans, G. F., Elsaid, M. I., Haring, B., Jung, S. Y., Kaplan, R., Kooperberg, C., Trejo, M. J., Wallace, R. B., Hagiwara, M., Karki, C., Nussbaum, T., Park, S., Ren, K., North, K. E., Below, J. E., & Clark, V. C. (2026). Epidemiology and diagnosis rates of alpha-1 antitrypsin deficiency-associated genotypes in the USA: a cross-sectional, multi-population study. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05519-5

Image Credits: AI Generated

DOI: 10.1186/s12876-026-05519-5

Keywords: Alpha-1 antitrypsin deficiency, AATD, Epidemiology, Genotype prevalence, All of Us Research Program, BioVU, Protease inhibitor ZZ, Underdiagnosis, Genetic screening, Electronic medical records, Liver disease, Lung disease, Thrombocytopenia, Public health genetics, Cross-sectional study, Clinical genomics

Tags:

 

Share Story:

Facebook
X
LinkedIn